Abstract:Alveolar echinococcosis (AE) is a highly lethal helminth infection. Current chemotherapeutic strategies for AE primarily involve the use of benzimidazoles (BZs) such as mebendazole (MDZ) and albendazole (ABZ), which exhibit limited efficacy. In a previous study, the vaccine of recombinant Echinococcus granulosus P29 (r Eg P29) showed significant immunoprotection against E . granulosus in both mice and sheep. In the current study, we utilized hybridoma technology to generate five monoclonal antibodies (mAbs) against P29, among which 4G10F4 mAb exhibited the highest antigen-specific binding capacity. This mAb was selected for further investigation of anti-AE therapy, both in vivo and in vitro. In vitro, 4G10F4 inhibited a noteworthy inhibition of E . multilocularis protoscoleces and primary cells viability through complement-dependent cytotoxicity (CDC) mechanism. In vivo, two experiments were conducted. In the first experiment, mice were intraperitoneally injected with Em protoscoleces, and subsequently treated with 4G10F4 mAb (2.5/5/10 mg/kg) at 12 weeks postinfection once per week for 8 times via tail vein injection. Mice that were treated with 4G10F4 mAb only in dosage of 5mg/kg exhibited a significant lower mean parasite burden (0.89±0.97 g) compared to isotype mAb treated control mice (2.21±1.30 g). In the second experiment, mice were infected through hepatic portal vein and treated with 4G10F4 mAb (5mg/kg) at one week after surgery once per week for 8 times. The numbers of hepatic metacestode lesions of the 4G10F4 treatment group were significantly lower in comparison to the isotype control group. Pathological analysis revealed severe disruption of the inner structure of the metacestode in both experiments, particularly affecting the germinal and laminated layers, resulting in the transformation into infertile vesicles after treatment with 4G10F4. In addition, the safety of 4G10F4 for AE treatment was confirmed through assessment of mouse weight and evaluation of liver and kidney function. This study presents antigen-specific monoclonal antibody immunotherapy as a promising therapeutic approach against E . multilocularis induced AE. Echinococcosis encompasses two significant zoonotic tapeworm diseases, cystic echinococcosis (CE) and alveolar echinococcosis (AE), caused by Echinococcus granulosus and Echinococcus multilocularis , respectively. AE is widely acknowledged as the most fatal helminth infection, with a mortality rate exceeding 90% within 10–15 years of diagnosis if left untreated or inadequately treated. Two benzimidazole carbamates, albendazole and mebendazole, are the only anti-infective drugs that are clinically efficient in interrupting the larval growth of Echinococcus spp. However, due to their toxicity and limited efficacy, there is a pressing need to explore novel therapeutic strategies for AE. In this study, a therapeutic antibody named 4G10F4 was produced against hydatid P29 using hybridoma technology. This candidate antibody significantly inhibited E . multilocularis both in vitro and in vivo, representing a potentially efficacious and safe antigen-specific monoclonal antibody immunotherapy for the treatment of AE. Additionally, it has been identified as a promising antibody drug and molecular target for the development of anti-AE therapy.

In Vitro and in Vivo Efficacies of the EGFR/MEK/ERK Signaling Inhibitors in the Treatment of Alveolar Echinococcosis

Current Status of Drug Therapy for Alveolar Echinococcosis

In Vitro and in Vivo Efficacies of Carbazole Aminoalcohols in the Treatment of Alveolar Echinococcosis.

Enhancing the therapeutic potential of P29 protein-targeted monoclonal antibodies in the management of alveolar echinococcosis through CDC-mediated mechanisms

Evaluation of Allicin Against Alveolar Echinococcosis in Vitro and in a Mouse Model

Impairing the maintenance of germinative cells in Echinococcus multilocularis by targeting Aurora kinase.

Efficacy and Safety of Asparagusic Acid against Echinococcus multilocularis In Vitro and in a Murine Infection Model

2-Deoxy-D-glucose and combined 2-Deoxy-D-glucose/albendazole exhibit therapeutic efficacy against <i>Echinococcus granulosus</i> protoscoleces and experimental alveolar echinococcosis

In Vitro Efficacy of Ampelopsin Against Echinococcus Granulosus and Echinococcus Multilocularis

In vivo effect of magnetic microspheres loaded with E2-a in the treatment of alveolar echinococcosis

Ubenimex Combined with Albendazole for the Treatment of Echinococcus Multilocularis-Induced Alveolar Echinococcosis in Mice

1,3-Substituted Β-Carboline Derivatives As Potent Chemotherapy for the Treatment of Cystic Echinococcosis.

Therapeutic effect on Alveolar echinococcosis by targeting EM-Leucine aminopeptidase

Suppressive effect of pseudolaric acid B on Echinococcus multilocularis involving regulation of TGF-β1 signaling in vitro and in vivo

Efficacy and mechanism of energy metabolism dual-regulated nanoparticles (atovaquone-albendazole nanoparticles) against cystic echinococcosis

Advances in the pharmacological treatment of hepatic alveolar echinococcosis: From laboratory to clinic

In vitro inhibitive effect of the anticancer drug sorafenib on Echinococcus multilocularis larvae

In Vitro Effects of Amino Alcohols on Echinococcus Granulosus

Effect of Anacardic Acid Against Echinococcosis Through Inhibition of VEGF-induced Angiogenesis

The susceptibility analysis of Echinococcus multilocularis protoscoleces tubulin to mebendazole and RNA interference

Drug repurposing for hard-to-treat human alveolar echinococcosis: pyronaridine and beyond